Intravitreal angiostatisk behandling af okulær sygdom

Lou-Ann Christensen Andersen; Lasse Jørgensen Cehofski; Jakob Grauslund

Intravitreal angiostatisk behandling af okulær sygdom

Lou-Ann Christensen Andersen, Lasse Jørgensen Cehofski, Jakob Grauslund

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Abstrakt

Intraocular vascular diseases like neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion are associated with decline in vision if left untreated. Anti-vascular endothelia growth factor (VEGF) agents originally developed for cancer treatment were the beginning of a new treatment regime for intraocular vascular diseases. Ambiguous results exist regarding adverse effects but are considered limited. In the future, anti-VEGF agents are likely to be used for treatment of proliferative diabetic retinopathy, neovascular glaucoma and premature retinopathy.

Bidragets oversatte titel	Intravitreal angiostatic treatment of ocular vascular diseases
Originalsprog	Dansk
Artikelnummer	V04190256
Tidsskrift	Ugeskrift for Laeger
Vol/bind	182
Udgave nummer	10
Antal sider	4
ISSN	0041-5782
Status	Udgivet - 2020

Dokumenter og links

http://ugeskriftet.dk/videnskab/intravitreal-angiostatisk-behandling-af-okulaer-sygdom

Fingeraftryk Dyk ned i forskningsemnerne om 'Intravitreal angiostatisk behandling af okulær sygdom'. Sammen danner de et unikt fingeraftryk.

Citationsformater

@article{c43b910b01214d66ac6433bba0dab9bb,

title = "Intravitreal angiostatisk behandling af okul{\ae}r sygdom",

abstract = "Intraocular vascular diseases like neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion are associated with decline in vision if left untreated. Anti-vascular endothelia growth factor (VEGF) agents originally developed for cancer treatment were the beginning of a new treatment regime for intraocular vascular diseases. Ambiguous results exist regarding adverse effects but are considered limited. In the future, anti-VEGF agents are likely to be used for treatment of proliferative diabetic retinopathy, neovascular glaucoma and premature retinopathy.",

author = "Andersen, {Lou-Ann Christensen} and {J{\o}rgensen Cehofski}, Lasse and Jakob Grauslund",

year = "2020",

language = "Dansk",

volume = "182",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "10",

}

TY - JOUR

T1 - Intravitreal angiostatisk behandling af okulær sygdom

AU - Andersen, Lou-Ann Christensen

AU - Jørgensen Cehofski, Lasse

AU - Grauslund, Jakob

PY - 2020

Y1 - 2020

N2 - Intraocular vascular diseases like neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion are associated with decline in vision if left untreated. Anti-vascular endothelia growth factor (VEGF) agents originally developed for cancer treatment were the beginning of a new treatment regime for intraocular vascular diseases. Ambiguous results exist regarding adverse effects but are considered limited. In the future, anti-VEGF agents are likely to be used for treatment of proliferative diabetic retinopathy, neovascular glaucoma and premature retinopathy.

AB - Intraocular vascular diseases like neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion are associated with decline in vision if left untreated. Anti-vascular endothelia growth factor (VEGF) agents originally developed for cancer treatment were the beginning of a new treatment regime for intraocular vascular diseases. Ambiguous results exist regarding adverse effects but are considered limited. In the future, anti-VEGF agents are likely to be used for treatment of proliferative diabetic retinopathy, neovascular glaucoma and premature retinopathy.

M3 - Tidsskriftartikel

VL - 182

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 10

M1 - V04190256

ER -